Gonadotropin-releasing hormone (GnRH) antagonist vs. gonadotropin-releasing hormone agonist protocol for in vitro fertilization in non-obese patients with Polycystic Ovary Syndrome (PCOS). A prospective randomized study.

Many clinical trials demonstrate that overall outcomes are comparable in GnRH agonists and antagonists protocols. However, recent data suggest that the duration of stimulation as well as the incidence of severe OHSS are significantly reduced in COH protocols with GnRH antagonist. There are only few studies comparing clinical outcome of GnRH agonist and antagonist protocols in PCOS patients. Nevertheless, none of those studies include a detailed embryological description. Because obesity was reported to be associated with relative gonadotropin resistance as well as lower number of collected oocytes we excluded obese patients. Mentioned studies did not consider high BMI as an exclusion criteria. In the current study, we decided to verify if women with PCOS can also benefit from GnRH antagonist protocol. Additionally, since the relative importance and the role of monitoring of LH in follicular development is still disputable we investigate correlation between LH levels and the treatment outcome.